Skip to main content

Carvykti Disease Interactions

There are 4 disease interactions with Carvykti (ciltacabtagene autoleucel).

Moderate

Ciltacabtagene autoleucel (applies to Carvykti) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Ciltacabtagene autoleucel has not been tested in patients with liver impairment. Caution and close monitoring are advised if used in these patients.

References

  1. (2022) "Product Information. Carvykti (ciltacabtagene autoleucel)." Janssen Biotech, Inc., 1
Moderate

Ciltacabtagene autoleucel (applies to Carvykti) hepatitis reactivation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis

Treatment with ciltacabtagene autoleucel may cause hypogammaglobulinemia. Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure and death, can occur in patients with hypogammaglobulinemia. Perform screening for cytomegalovirus (CMV), HBV, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) or any other viral infectious agents in accordance with clinical guidelines before collection of cells for manufacturing and treatment with this agent. Consider antiviral therapy to prevent viral reactivation per local institutional guidelines and clinical practice.

References

  1. (2022) "Product Information. Carvykti (ciltacabtagene autoleucel)." Janssen Biotech, Inc., 1
Moderate

Ciltacabtagene autoleucel (applies to Carvykti) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Ciltacabtagene autoleucel should not be administered to patients with active infection or inflammatory disorders. Severe, life-threatening, or fatal infections have occurred in patients after infusion with this drug. Active infections should be treated before treatment initiation.

References

  1. (2022) "Product Information. Carvykti (ciltacabtagene autoleucel)." Janssen Biotech, Inc., 1
Moderate

Ciltacabtagene autoleucel (applies to Carvykti) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Ciltacabtagene autoleucel has not been tested in patients with renal impairment. Caution and close monitoring are advised if used in these patients.

References

  1. (2022) "Product Information. Carvykti (ciltacabtagene autoleucel)." Janssen Biotech, Inc., 1

Carvykti drug interactions

There are 198 drug interactions with Carvykti (ciltacabtagene autoleucel).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer